$OXIS Retains The Emmes Group To Assist With Its Strategic Business

“I am pleased to again have the opportunity to work with the Emmes Group, and Martin Schroeder, EVP & Managing Director,” said Anthony Cataldo, Chairman and Chief Executive Officer.  “Mr. Schroeder and his colleagues at the Emmes Group were responsible for helping me to identify the cell therapy assets, and developing and executing the business initiatives and licensing strategies which were the foundation of Genesis Biopharma now known as Lion Biotechnologies (LBIO),” Mr. Cataldo further stated.

Oxis has retained several key, industry leading individuals as scientific advisory board members, and in corporate management consultative capacities.  The Company believes that by assembling a well-versed and well-seasoned group of individuals involved in different facets of the Oxis business model, the Company will be able to successfully execute and achieve its corporate and therapeutic development goals.

“Our goal at Oxis Biotech is to build a leading cancer immunotherapy company focused on platform technologies including bispecific immune cell engagers, antibody-drug conjugates (ADCs), and novel small molecule therapeutics targeting B-cell malignancies and certain solid tumors such as triple negative breast cancer,” said Mr. Cataldo.

About the Emmes Group

The Emmes Group is a strategy consulting firm supporting companies engaged in the technology and healthcare industries.  Our partners have over 50 years of combined experience.  We work in partnership with our clients to increase profits and build lasting economic value.  Our expertise spans a number of key areas, including: strategy consulting, partnerships, mergers & acquisitions, strategic marketing, market research & modeling, business development, technology licensing, corporate finance, and investor due diligence.  For more information about the Emmes Group, please visit https://www.emmesgroup.com.

About Oxis Biotech, Inc.

Oxis Biotech is a cancer immunotherapy company developing innovative therapies focused on the treatment of cancer.  Oxis’ immunotherapy platform includes bispecific immune cell engagers, antibody-drug conjugates (ADCs), and novel small molecule therapeutics targeting B-cell malignancies and certain solid tumors such as triple negative breast cancer.  OXIS’ lead drug candidate, OXS-2175, is being developed for the treatment of triple-negative breast cancer.  In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.  OXIS’ lead drug candidate, OXS-4235, is being developed for the treatment of multiple myeloma and associated osteolytic lesions.  In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.  For more information about Oxis Biotech, please visithttps://www.oxis.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Jonathon Barkman
Riverview Capital Enterprises
P.866.845.0105

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/oxis-biotech-retains-the-emmes-group-to-assist-with-its-strategic-business-and-therapeutic-development-initiatives-300081630.html